Advanced

Management of relapsed multiple myeloma: Recommendations of the international myeloma working group.

Laubach, J; Garderet, L; Mahindra, A; Gahrton, G; Caers, J; Sezer, O; Voorhees, P; Leleu, X; Johnsen, H E and Streetly, M, et al. (2015) In Leukemia 30. p.1005-1017
Abstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation,... (More)
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.Leukemia accepted article preview online, 29 December 2015. doi:10.1038/leu.2015.356. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
30
pages
1005 - 1017
publisher
Nature Publishing Group
external identifiers
  • PMID:26710887
  • Scopus:84958074272
ISSN
1476-5551
DOI
10.1038/leu.2015.356
language
English
LU publication?
yes
id
ab2baf8d-c502-435f-af59-2358321fa2be (old id 8500319)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26710887?dopt=Abstract
date added to LUP
2016-01-06 19:42:00
date last changed
2016-10-30 04:37:22
@misc{ab2baf8d-c502-435f-af59-2358321fa2be,
  abstract     = {The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.Leukemia accepted article preview online, 29 December 2015. doi:10.1038/leu.2015.356.},
  author       = {Laubach, J and Garderet, L and Mahindra, A and Gahrton, G and Caers, J and Sezer, O and Voorhees, P and Leleu, X and Johnsen, H E and Streetly, M and Ludwig, H and Mellqvist, U-H and Chng, W-J and Pilarski, L and Einsele, H and Hou, J and Turesson, Ingemar and Zamagni, E and Chim, J and Mazumder, A and Westin, J and Lu, J and Reiman, T and Kristinsson, S and Joshua, D and Roussel, M and O'Gorman, P and Terpos, E and Dimopoulos, M and Moreau, P and Anderson, K and Palumbo, A and Kumar, S and Rajkumar, V and Durie, B and Richardson, P},
  issn         = {1476-5551},
  language     = {eng},
  month        = {12},
  pages        = {1005--1017},
  publisher    = {ARRAY(0x7f877e8)},
  series       = {Leukemia},
  title        = {Management of relapsed multiple myeloma: Recommendations of the international myeloma working group.},
  url          = {http://dx.doi.org/10.1038/leu.2015.356},
  volume       = {30},
  year         = {2015},
}